
    
      To determine whether a strategy of Vectra DA guided care (Arm A), compared with usual care
      (Arm B), achieves non-inferior clinical outcomes while reducing the cost of treatment in
      patients with active RA and an inadequate response to MTX monotherapy.
    
  